domingo, 27 de noviembre de 2016

Survival and Prognostic Ability in Lung Cancer With Brain Metastases | Genetics and Genomics | JAMA Oncology | The JAMA Network

Survival and Prognostic Ability in Lung Cancer With Brain Metastases | Genetics and Genomics | JAMA Oncology | The JAMA Network

November 17, 2016
Estimating Survival in Patients With Lung Cancer and Brain Metastases
An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)
Paul W. Sperduto, MD, MPP1,2; T. Jonathan Yang, MD3; Kathryn Beal, MD3; et al Hubert Pan, MD4; Paul D. Brown, MD4; Ananta Bangdiwala, MS5; Ryan Shanley, MS5; Norman Yeh, MD6; Laurie E. Gaspar, MD, MBA6; Steve Braunstein, MD7; Penny Sneed, MD7; John Boyle, MD8; John P. Kirkpatrick, MD, PhD8; Kimberley S. Mak, MD9; Helen A. Shih, MD9; Alex Engelman, MD10; David Roberge, MD11; Nils D. Arvold, MD12; Brian Alexander, MD12; Mark M. Awad, MD, PhD13; Joseph Contessa, MD13; Veronica Chiang, MD13; John Hardie, MD, PhD14; Daniel Ma, MD14; Emil Lou, MD15; William Sperduto, BA8; Minesh P. Mehta, MD10
Author Affiliations
JAMA Oncol. Published online November 17, 2016. doi:10.1001/jamaoncol.2016.3834

No hay comentarios:

Publicar un comentario en la entrada